Anti-epileptic Agent
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Anti-epileptic Agent
Anti-epileptic Agent drugs are designed to control or prevent seizures by modulating neuronal excitability in the brain. These agents typically work by targeting ion channels, neurotransmitter systems, or other molecular pathways that influence neuronal firing. The primary approved indication for this class is epilepsy, encompassing various seizure types such as tonic-clonic, psychomotor, and partial-onset seizures. The first-in-class drug, DILANTIN-125 (phenytoin), was approved in 1953 by Viatris, establishing a foundational treatment. Subsequent years saw the introduction of MYSOLINE (primidone) in 1954 and ZARONTIN (ethosuximide) in 1960, broadening the therapeutic options.
The field has evolved with the development of newer agents offering improved efficacy, tolerability, and broader seizure type coverage. LAMICTAL (lamotrigine), approved in 1994 by GSK, and TRILEPTAL (oxcarbazepine) in 2000 by Novartis, represent advancements in managing epilepsy. More recent introductions include ZONEGRAN (zonisamide) in 2000 by ADVANZ PHARMA, and extended-release formulations like LAMICTAL XR and LAMICTAL ODT, along with OXTELLAR XR for oxcarbazepine. The class also includes drugs like SABRIL (vigabatrin) and its newer counterpart VIGAFYDE, targeting specific seizure types like infantile spasms.
Looking ahead, the landscape of anti-epileptic agents is characterized by ongoing efforts to refine existing therapies and explore novel mechanisms. While the core indication remains epilepsy, research is expanding into related neurological conditions. The development of extended-release formulations and drugs with improved safety profiles continues to be a focus, aiming to enhance patient adherence and reduce adverse effects. The introduction of VIGAFYDE in 2024 signifies continued innovation, particularly for rare seizure disorders.
22 FDA-approved Anti-epileptic Agent drugs, including DILANTIN-125, with 16 active Phase 3 trials across 2 indications from 2 active sponsors. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Anti-epileptic Agent Drugs
22 totalAnti-epileptic Agent drugs originated with the introduction of DILANTIN-125 (phenytoin) by Viatris in 1953, a cornerstone therapy for tonic-clonic and psychomotor seizures. This was followed by MYSOLINE (primidone) in 1954 and ZARONTIN (ethosuximide) in 1960, both originating from PARKE-DAVIS. The evolution of this class saw the emergence of second-generation drugs like LAMICTAL (lamotrigine) from GSK in 1994 and TRILEPTAL (oxcarbazepine) from Novartis in 2000, offering improved tolerability and efficacy profiles for epilepsy and partial-onset seizures. Further refinements included ZONEGRAN (zonisamide) in 2000 by ADVANZ PHARMA, and advanced formulations like LAMICTAL ODT and LAMICTAL XR, and OXTELLAR XR, extending treatment options and convenience. Individual Anti-epileptic Agent drugs differentiate themselves through their specific mechanisms, efficacy in various seizure types, and pharmacokinetic profiles. For instance, ethosuximide remains a primary choice for absence seizures, while lamotrigine offers broad-spectrum coverage for epilepsy and partial-onset seizures. Oxcarbazepine and its extended-release form OXTELLAR XR provide options for partial-onset seizures, with differing dosing schedules. Vigabatrin, available as SABRIL and the newer VIGAFYDE, is specifically indicated for complex partial seizures and infantile spasms, highlighting a niche application within the broader class. These differences influence their positioning in treatment algorithms, with some drugs favored for specific seizure types or patient populations. Today, Anti-epileptic Agent drugs form the backbone of epilepsy management, with many older agents now available as generics, leading to significant price competition. Newer agents and formulations are often employed as first- or second-line treatments, particularly for partial-onset seizures and refractory epilepsy. The originator drugs, while still relevant, face competition from generic versions, impacting market dynamics. For example, Viatris's DILANTIN-125 and VALEANT's MYSOLINE, though originating decades ago, continue to be prescribed. The introduction of VIGAFYDE in 2024 by PYROS PHARMS for infantile spasms indicates ongoing innovation in addressing specific, often severe, seizure conditions within the anti-epileptic armamentarium.
Anti-epileptic Agent Indications in Trials
Active industry trialsThe active Phase 2/3 pipeline for Anti-epileptic Agent drugs shows limited but focused activity, with the most significant concentration in Bipolar Disorder Type I With Mania, currently boasting one active trial. While epilepsy remains the primary approved indication for this class, the pipeline data suggests a strategic exploration into adjacent central nervous system disorders, leveraging the known mechanisms of neuronal modulation. The single active trial in bipolar disorder indicates a potential expansion beyond traditional seizure control, aiming to address mood stabilization through similar pharmacological pathways. The expansion frontier for Anti-epileptic Agent drugs appears to be primarily in indications beyond their core epilepsy approvals. The single active trial in Bipolar Disorder Type I With Mania represents a significant deviation from the historical focus on seizure disorders. This suggests a strategic pivot by some sponsors to explore the broader psychotropic effects of these agents, potentially targeting underlying neuronal excitability or neurotransmitter imbalances implicated in mood disorders. There is no data indicating novel patient subpopulations, combination regimens, or modality trends beyond oral formulations within the provided active Phase 2/3 trial information. Looking at the next 6-12 months for Anti-epileptic Agent drugs, the pipeline appears relatively quiet in terms of broad activity, with only one active trial identified in Bipolar Disorder Type I With Mania. This suggests that major breakthroughs or new indications are not imminent in the immediate future based on current Phase 2/3 development. The lack of multiple active trials in epilepsy or other neurological conditions might indicate a mature market for established mechanisms or a shift in R&D focus towards earlier-stage research or different therapeutic classes. The single trial in bipolar disorder is the primary catalyst to watch, as its outcome could inform future development in mood disorders.
Top Anti-epileptic Agent Sponsors
Industry trials, any indicationBristol-Myers Squibb is the dominant player in the current active Phase 2/3 industry trials for Anti-epileptic Agent drugs, with one active trial. This lead is attributed to their strategic focus on exploring the potential of these agents in indications beyond epilepsy, specifically in Bipolar Disorder Type I With Mania. While the trial count is modest, their engagement signifies a commitment to leveraging their expertise in CNS therapeutics to expand the utility of this drug class, potentially building on existing knowledge of neuronal modulation. Key challengers in the Anti-epileptic Agent space are not explicitly detailed by trial count in the provided data beyond Bristol-Myers Squibb's single active trial. However, the presence of multiple originator and generic manufacturers for approved drugs like Viatris (DILANTIN-125), VALEANT (MYSOLINE), GSK (LAMICTAL), Novartis (TRILEPTAL), and others indicates a competitive landscape for existing indications. These companies, along with generic entrants, continue to compete on efficacy, safety, and cost for epilepsy management. The strategic landscape for Anti-epileptic Agent drugs is largely defined by the established market for epilepsy, where generic competition is prevalent. Bristol-Myers Squibb's single active trial in bipolar disorder represents a strategic move to diversify beyond this mature market. Geographic positioning is not specified for this trial. Upcoming catalysts are limited, with the primary focus being the progression and outcome of Bristol-Myers Squibb's bipolar disorder trial. For investors or BD scouts, this suggests an opportunity in exploring novel indications or developing next-generation therapies with differentiated profiles, as the core epilepsy market is well-served by existing generics and established brands.
Anti-epileptic Agent Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved Anti-epileptic Agent drugs across 2 indications from 2 sponsors. Earliest readout: Q2 2025.
Coverage: trials whose intervention is an approved Anti-epileptic Agent drug. Pre-approval candidates with development codes are not yet linked.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.